KPM Tech·Telcon RF Pharma "Humanigen Applies for Nasdaq Listing"

[Asia Economy Reporter Hyunseok Yoo] KPM Tech and TelconRF Pharmaceutical announced on the 7th that Humanigen has applied to the U.S. Securities and Exchange Commission (SEC) for approval of common stock for listing on the Nasdaq.

KPM Tech and TelconRF Pharmaceutical invested 4.9 billion KRW in Humanigen last month. They each hold 2.3 million shares, totaling 4.6 million shares.

Humanigen is a cell and gene therapy development company located in San Francisco, USA, with its main pipeline being Lenzilumab.

Lenzilumab is currently undergoing Phase 3 clinical trials in the U.S. as a treatment for COVID-19. Recently, it also began the first dosing in a combination therapy clinical trial with Yescarta, an immune cell therapy from KITE, a subsidiary of Gilead Sciences.

Humanigen closed trading on the U.S. over-the-counter market (OTCQB) at $4.40 per share on the 6th. This is an increase of over 400% compared to the purchase price of $0.87 per share at which KPM Tech and TelconRF Pharmaceutical invested.

A KPM Tech official stated, “Investing in a company with a promising pipeline is showing results in a short period,” and added, “We expect the stock price to gain further momentum upon Humanigen’s Nasdaq listing.”